A study to investigate the pharmacokinetics and safety of dupilumab in participants ≥6 months to <18 years of age with prurigo nodularis

Trial Identifier: PKM17836
Sponsor: Sanofi
Collaborator:
Regeneron Pharmaceuticals
Start Date: May 2024
Primary Completion Date: October 2027
Study Completion Date: November 2027
Condition: Dermatitis and Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
UNITED STATES, California PALO ALTO, California, UNITED STATES, 94304
UNITED STATES, California RANCHO SANTA MARGARITA, California, UNITED STATES, 92688
UNITED STATES, Florida CORAL GABLES, Florida, UNITED STATES, 33146
UNITED STATES, Florida CORAL SPRINGS, Florida, UNITED STATES, 33071
UNITED STATES, Florida HIALEAH, Florida, UNITED STATES, 33012
UNITED STATES, Florida LUTZ, Florida, UNITED STATES, 33558
UNITED STATES, Florida TAMPA, Florida, UNITED STATES, 33606
UNITED STATES, Minnesota EAGAN, Minnesota, UNITED STATES, 55123
UNITED STATES, Missouri ST. JOSEPH, Missouri, UNITED STATES, 64506
UNITED STATES, North Dakota FARGO, North Dakota, UNITED STATES, 58103
UNITED STATES, Oklahoma TULSA, Oklahoma, UNITED STATES, 74136
UNITED STATES, Texas AUSTIN, Texas, UNITED STATES, 78723
UNITED STATES, Texas CORPUS CHRISTI, Texas, UNITED STATES, 78411
UNITED STATES, Texas SAN ANTONIO, Texas, UNITED STATES, 78218